|

NEO-201 in combination with pembrolizumab Clinical Trials

1 actively recruiting trial across 1 location

Also known as: IHC screening for NEO-201 target

Pipeline

Phase 1/2: 1

Top Sponsors

  • Precision Biologics, Inc1

Indications

  • Uterine Cancer1
  • Head and Neck Squamous Cell Carcinoma1
  • Cervical Cancer1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1

Bethesda, Maryland1 trial

Study of NEO-201 in Solid Tumors Expansion Cohorts

National Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.